Osteoporosis | Treatment Algorithms: Claims Data Analysis | US | 2024

A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents like Amgen’s Prolia and Evenity, as well as Radius Health’s Tymlos, are reserved for high-risk patients, primarily because of their high prices. As the treatment landscape for osteoporosis continues to evolve, this report offers insight based on real-world claims data into prescribing trends to help new players understand current treatment practices and to define the market niche for their emerging products.

Questions answered

• What shares do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
• How has Evenity been integrated into the treatment algorithm, and what is its source of business?
• What percentage of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
• What percentage of osteoporosis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Eli Lilly, Radius Health, Amgen

Key drugs: Oral bisphosphonates, zoledronate, Prolia, teriparatide, Tymlos, Evenity

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses